ArticleCancer medicine2023

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Toshifumi Tada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.